World Health Organization. Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed 4 Dec 2021
Torjesen I. Covid-19 will become endemic but with decreased potency over time, scientists believe. BMJ. 2021;372: n494.
Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination against SARS-CoV-2: a systematic review of existing strategies and guidelines. Vaccines. 2021;9(4):326.
Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19). Our World Data. 2020. https://ourworldindata.org/covid-vaccinations. Assessed 6 Dec 2021.
What are whole virus vaccines and how could they be used against COVID-19. https://www.gavi.org/vaccineswork/what-are-whole-virus-vaccines-and-how-could-they-be-used-against-covid-19. Assessed 5 Dec 2021.
Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical outcomes of A COVID-19 vaccine: implementation over efficacy. Health Affairs (Project Hope). 2021;40(1):42–52.
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: a test-negative case-control study. The BMJ. 2021;373: n1088.
Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw Open. 2021;4(6): e2115985.
Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine—United States, September 6, 2020–May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):858–64.
White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-CoV-2 infection among mRNA-vaccinated and unvaccinated nursing home residents. New Engl J Med. 2021;385(5):474–6.
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B117: an ecological study. Lancet Public Health. 2021;6(5):e335–45.
Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status—13 US jurisdictions, April 4–July 17, 2021. MMWR. 2021;70(37):1284–90.
Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, Gounder P, Jarashow C, Balter S. SARS-CoV-2 infections and hospitalizations among persons aged ≥16 years, by vaccination status—Los Angeles County, California, May 1–July 25, 2021. MMWR. 2021. https://doi.org/10.15585/mmwr.mm7034e5.
Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years—COVID-NET, 13 states, January 1–July 24, 2021. MedRxiv. 2021. https://doi.org/10.1101/2021.08.27.21262356v1.
Ministry of Health. Coronavirus. Tunis, 2021. http://coronavirus.rns.tn/. Assessed 8 Dec 2021.
Ministry of Health. Vaccination Strategy against covid-19. Tunis, 2021. http://www.santetunisie.rns.tn/images/strategie-vaccination-covid-19.pdf. Assessed 13 Nov 2021.
Ministry of Health. National Dashboard of coronavirus Vaccination. Tunis, 2021. https://evax.tn/vaccinationOD.html. Assessed 13 Nov 2021.
National Institute of Statistics. Statistics of Tunisian population. Tunis, 2021. http://www.ins.tn/statistiques/111. Assessed 12 Oct 2021.
National Observatory of New and Emerging Diseases. Definition of COVID-19 cases in Tunisia. Tunis, 2020. https://www.onmne.tn/?p=10305. Assessed 20 Jan 2022.
Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Lancet Microbe. 2021;2(7):e279–80.
Stouten V, Hubin P, Haarhuis F, van Loenhout JAF, Billuart M, Brondeel R, et al. Incidence and risk factors of COVID-19 vaccine breakthrough infections: a prospective cohort study in Belgium. Viruses. 2022;14(4):802.
Brunelli SM, Sibbel S, Karpinski S, Marlowe G, Walker AG, Giullian J, et al. Comparative effectiveness of mRNA-based BNT162b2 vaccine versus adenovirus vector-based Ad26COV2S vaccine for the prevention of COVID-19 among dialysis patients. J Am Soc Nephrol. 2022;33(4):688–97.
Bosch W, Cowart JB, Bhakta S, Carter RE, Wadei HM, Shah SZ, et al. COVID-19 vaccine-breakthrough infections requiring hospitalization in mayo clinic florida through August 2021. Clin Infec Dis. 2021. https://doi.org/10.1093/cid/ciab932.
Butt AA, Yan P, Shaikh OS, Mayr FB, Omer SB. Rate and risk factors for severe/critical disease among fully vaccinated persons with breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a high-risk national population. Clin Infec Dis. 2021. https://doi.org/10.1093/cid/ciab1023.
Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes, and impact. Nat Rev Immunol. 2022;22(1):57–65.
Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
Lakbar I, Luque-Paz D, Mege J-L, Einav S, Leone M. COVID-19 gender susceptibility and outcomes: a systematic review. PLoSONE. 2020;15(11): e0241827.
Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–7.
Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022;108(1):73–9.
Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, et al. Innate immune receptors, key actors in cardiovascular diseases. JACC Basic Transl Sci. 2020;5(7):735–49.
Li Q, Wang Y, Sun Q, Knopf J, Herrmann M, Lin L, et al. Immune response in COVID-19: what is next? Cell Death Differ. 2022;29(6):1107–22.
Kearns P, Siebert S, Willicombe M, Gaskell C, Kirkham A, Pirrie S, et al. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity—the OCTAVE Trial. Rochester, NY: Social Science Research Network; 2021. Report No.: ID 3910058.
Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, et al. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B16172) variant era. Lancet Microbe. 2022;3(1):e4-5.
Tran TNA, Wikle NB, Albert E, Inam H, Strong E, Brinda K, et al. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts. BMC Med. 2021;19:162.
Bhattacharya A, Ranjan P, Ghosh T, Agarwal H, Seth S, Maher GT, et al. Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: a single centre, cross-sectional analytical study from India. Diabetes Metab Syndr. 2021;15(5): 102238.
Alcendor DJ, Matthews-Juarez P, Smoot D, Hildreth JE, Lamar K, et al. Breakthrough COVID-19 infections in the US: implications for prolonging the pandemic. Vaccines. 2022;10(5):755.
Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. The BMJ. 2021;374: n1943.
Li L, Han Z-G, Qin P-Z, Liu W-H, Yang Z, Chen Z-Q, et al. Transmission and containment of the SARS-CoV-2 delta variant of concern in Guangzhou, China: a population-based study. PLoS Negl Trop Dis. 2022;16(1): e0010048.
Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. New Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2108891.
Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–26.
World Health Organization. The effects of virus variants on COVID-19 vaccines. Geneva, 2021. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines. Accessed 30 Aug 2022
Chouikha A, Fares W, Laamari A, Haddad-Boubaker S, Belaiba Z, Ghedira K, et al. Molecular epidemiology of SARS-CoV-2 in Tunisia (North Africa) through several successive waves of COVID-19. Viruses. 2022;14(3):624.
Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, et al. Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021. https://doi.org/10.1080/14760584.2021.1903879.
Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet Lond Engl. 2021;398(10309):1407–16.
Bates TA, McBride SK, Winders B, Schoen D, Trautmann L, Curlin ME, et al. Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection. JAMA. 2022;327(2):179–81.